聚乙二醇干扰素联合胸腺法新治疗慢性乙型肝炎的疗效观察

Therapeutic Effect of Peginterferon Combined With Thymus Method in the Treatment of Chronic Hepatitis B

目的观察聚乙二醇干扰素与胸腺法新联合治疗慢性乙型病毒性肝炎的临床疗效。方法选取2012年8月—2015年5月在我院肝病科进行慢性乙型肝炎疾病治疗的患者共62例作为研究对象,并按照随机性原则,将62例患者划分为对照组和治疗组。对照组患者行聚乙二醇干扰素治疗,治疗组患者则在聚乙二醇干扰素治疗基础上,联合胸腺法新治疗,两组聚乙二醇干扰素治疗药物剂量、药用方法及疗程等一致。观察治疗前后的临床症状和肝功能、HBV-DNA等指标的变化。结果治疗组患者的血清HBV-DNA阴转率为21例(67.7%),HBeAg的阴转率为18例(58.1%)以及血清抗-Hbe阳转率为14例(45.2%),均高于对照组的14例(45.2%)、11例(35.5%)、8例(25.8%),差异均具有统计学意义(P<0.05)。治疗组患者的有效应答率为83.9%,对照组有效应答率61.3%,治疗组的有效应答率优于对照组,差异具有统计学意义(P<0.05)。结论表明聚乙二醇干扰素和胸腺法新联合治疗慢性乙型病毒性肝炎疗效优于单用聚乙二醇干扰素治疗。

Objective To observe the clinical efcacy of a new combination of peginterferon and thymus in the treatment of chronic viral hepatitis B. Methods A total of 62 patients who received chronic hepatitis B treatment in our hospital from August 2012 to May 2015 were selected as the studysubjects. According to the principle of randomness, 62 patients were divided into two groups, the control group and the treatment group. The control group was treated with peginterferon, and the treatment group was treated with peginterferon combined with thymus. The two groups were consistent with the dose, the medical method and the treatment course. The changes of clinical symptoms, liver function, HBV-M, HBV-DNA and other indexes were observed before and after treatment. Results The patients in the treatment group the serum HBV-DNA negative rate was 21 cases （67.7%）, transfer rate of HBeAg was 18 cases （58.1%） of negative conversion rate and serum anti-Hbe positive for 14 cases （45.2%） were higher than the control group, 14 cases （45.2%）, 11 cases （35.5%）, 8 cases （25.8%）. The differences were statistically significant （P 〈 0.05）. The effective response rate of the treatment group was 83.9%, while the efective rate of the control group was 61.3%. The efective response rate in the treatment group was better than that in the control group, the diference was statistically signifcant （P 〈 0.05）. Conclusion The therapeutic efect of peginterferon and thymus method in the treatment of chronic hepatitis B is better than that of peginterferon alone.